1. Metabolic Enzyme/Protease
  2. Angiotensin-converting Enzyme (ACE)
  3. Captopril

Captopril (SQ 14225), antihypertensive agent, is a thiol-containing competitive, orally active angiotensin-converting enzyme (ACE) inhibitor (IC50=0.025 μM) and has been widely used for research of hypertension and congestive heart failure. Captopril is also a New Delhi metallo-β-lactamase-1 (NDM-1) inhibitor with an IC50 of 7.9 μM.

For research use only. We do not sell to patients.

CAS No. : 62571-86-2

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
25 mg In-stock
50 mg In-stock
100 mg In-stock
500 mg In-stock
1 g   Get quote  
5 g   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 22 publication(s) in Google Scholar

Other Forms of Captopril:

Top Publications Citing Use of Products

    Captopril purchased from MedChemExpress. Usage Cited in: Allergy. 2025 Nov 14.  [Abstract]

    Representative images of feet collected 30 min post-Evans Blue (EB) injection. Mice were assigned to five groups: WT control, Serping1+/− control, WT + Captopril (2.5 mg/kg; i.v.), Serping1+/− + Captopril + PBS, and Serping1+/− + Captopril + AAV-NG-ABE8e. Captopril elicited significant Evans blue leakage.

    Captopril purchased from MedChemExpress. Usage Cited in: Allergy. 2025 Nov 14.  [Abstract]

    Representative intravital confocal images showing real-time FITC-dextran extravasation from intestinal microvasculature. Mice were assigned to: WT control, Serping1+/− control, WT + Captopril (2.5 mg/kg; i.v.), Serping1+/− + Captopril + PBS, and Serping1+/− + Captopril + AAV-NG-ABE8e. By 30 min, Captopril-treated mice demonstrated pronounced FITC-dextran extravasation—both in area and fluorescence intensity—relative to WT and Serping1+/− controls.

    Captopril purchased from MedChemExpress. Usage Cited in: Nat Commun. 2023 May 2;14(1):2523.  [Abstract]

    Serum BK levels from sWAT from WT male mice treated with 40 mg/kg/day Captopril or 70 mg/kg/day Enalapril by gavage once a day for 21 days. The results showed that Captopril significantly increased serum BK levels.

    Captopril purchased from MedChemExpress. Usage Cited in: Nat Commun. 2023 May 2;14(1):2523.  [Abstract]

    Representative immunohistochemistry (IHC) staining of UCP1 and H&E staining of sWAT. Captopril (40 mg/kg; once daily; 21 days; 25°C) induced sWAT brownin.

    Captopril purchased from MedChemExpress. Usage Cited in: Nat Commun. 2023 May 2;14(1):2523.  [Abstract]

    Captopril (40 mg/kg; once daily; 21 days; 25°C) decreased the weight of sWAT in WT male mice.
    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Captopril (SQ 14225), antihypertensive agent, is a thiol-containing competitive, orally active angiotensin-converting enzyme (ACE) inhibitor (IC50=0.025 μM) and has been widely used for research of hypertension and congestive heart failure. Captopril is also a New Delhi metallo-β-lactamase-1 (NDM-1) inhibitor with an IC50 of 7.9 μM[1][2][3].

    IC50 & Target

    ACE[1].

    Cellular Effect
    Cell Line Type Value Description References
    HeLa EC50
    130 μM
    Compound: L-A1
    Cytotoxicity against human HeLa cells incubated for 72 hrs by alamar blue cell viability assay
    Cytotoxicity against human HeLa cells incubated for 72 hrs by alamar blue cell viability assay
    [PMID: 39013490]
    KB 3-1 IC50
    15.67 mM
    Compound: captropril
    Cytotoxicity against human KB-3-1 cells incubated for 72 hrs by MTT assay
    Cytotoxicity against human KB-3-1 cells incubated for 72 hrs by MTT assay
    [PMID: 21657271]
    KB-V1 IC50
    13.07 mM
    Compound: captropril
    Cytotoxicity against drug-resistant human KBV1 cells expressing P-gp incubated for 72 hrs by MTT assay
    Cytotoxicity against drug-resistant human KBV1 cells expressing P-gp incubated for 72 hrs by MTT assay
    [PMID: 21657271]
    In Vitro

    Captopril (SQ 14225) has been shown to have similar morbidity and mortality benefits to those of diuretics and beta-blockers in hypertensive patients. Captopril has been shown to delay the progression of diabetic nephropathy, and enalapril and lisinopril prevent the development of nephropathy in normoalbuminuric patients with diabetes[4].
    An equimolar ratio of the cis and trans states of Captopril exists in solution and that the enzyme selects only the trans state of the inhibitor that presents architectural and stereoelectronic complementarity with its substrate binding groove[5].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Clinical Trial
    Molecular Weight

    217.29

    Formula

    C9H15NO3S

    CAS No.
    Appearance

    Solid

    Color

    White to yellow

    SMILES

    O=C(O)[C@H]1N(C([C@H](C)CS)=O)CCC1

    Shipping

    Room temperature in continental US; may vary elsewhere.

    Storage
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 6 months
    -20°C 1 month
    Solvent & Solubility
    In Vitro: 

    DMSO : ≥ 50 mg/mL (230.11 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    H2O : ≥ 50 mg/mL (230.11 mM)

    *"≥" means soluble, but saturation unknown.

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 4.6021 mL 23.0107 mL 46.0214 mL
    5 mM 0.9204 mL 4.6021 mL 9.2043 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    * Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.5 mg/mL (11.51 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 2.5 mg/mL (11.51 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

    For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  PBS

      Solubility: 32.5 mg/mL (149.57 mM); Clear solution; Need ultrasonic

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Calculation results:
    Working solution concentration: mg/mL
    This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).
    Purity & Documentation

    Purity: 99.84%

    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO / H2O 1 mM 4.6021 mL 23.0107 mL 46.0214 mL 115.0536 mL
    5 mM 0.9204 mL 4.6021 mL 9.2043 mL 23.0107 mL
    10 mM 0.4602 mL 2.3011 mL 4.6021 mL 11.5054 mL
    15 mM 0.3068 mL 1.5340 mL 3.0681 mL 7.6702 mL
    20 mM 0.2301 mL 1.1505 mL 2.3011 mL 5.7527 mL
    25 mM 0.1841 mL 0.9204 mL 1.8409 mL 4.6021 mL
    30 mM 0.1534 mL 0.7670 mL 1.5340 mL 3.8351 mL
    40 mM 0.1151 mL 0.5753 mL 1.1505 mL 2.8763 mL
    50 mM 0.0920 mL 0.4602 mL 0.9204 mL 2.3011 mL
    60 mM 0.0767 mL 0.3835 mL 0.7670 mL 1.9176 mL
    80 mM 0.0575 mL 0.2876 mL 0.5753 mL 1.4382 mL
    100 mM 0.0460 mL 0.2301 mL 0.4602 mL 1.1505 mL

    * Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

     

    Requested Quantity *

    Applicant Name *

     

    Salutation

    Email Address *

     

    Phone Number *

    Department

     

    Organization Name *

    City

    State

    Country or Region *

         

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Captopril
    Cat. No.:
    HY-B0368
    Quantity:
    MCE Japan Authorized Agent: